We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA WANTS HT MAKERS TO ADD DEMENTIA RISK TO LABELING
FDA WANTS HT MAKERS TO ADD DEMENTIA RISK TO LABELING
February 13, 2004
The makers of hormone therapy (HT) products need to revise their labeling to include data from a clinical study that found women over 65 had an increased risk of dementia when taking oral conjugated estrogens plus medroxyprogesterone acetate, the FDA said last week.